BDXBecton Dickinson
Price
+26%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications.
In the company’s own words · 10-K filed Nov 25, 2025 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Becton Dickinson (BDX) reported revenue of $4.98B in Q3 2026 (quarter ended Jun 30, 2026), up 5.4% from the same quarter a year earlier. That came with a gross margin of 46% and net income of $377M (7.6% of revenue). For the full year FY2025, revenue was $21.8B (+8.2% year on year) and net income $1.68B. Its largest segment in Q3 2026 was Connected Care at $737M, 38% of the disclosed total, just ahead of Medical Essentials at 37%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026BD Reports Third Quarter Fiscal 2026 Financial Results.Earnings release · press release
- Jul 22, 2026On July 19, 2026, Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire.Director or officer change · Form 8-K
- May 20, 2026Subsidiary Notes Offering On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg (“Becton Finance”) and an indirect, wholly-owned subsidiary of Becton, Dickinson and Company (“BD”) …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2026 · $1.96BThe company’s own SEC segment disclosure.
- Connected Care$737.0M38%
- Medical Essentials$720.0M37%
- Interventional$294.0M15%
- Bio Pharma Systems$204.0M10%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
The closest names by size in the same industry